Intra-Cellular Therapies, Inc. | Date: 2015-04-03
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
Intra-Cellular Therapies, Inc. | Date: 2015-10-16
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinsons disease or any combinations.
Intra-Cellular Therapies, Inc. | Date: 2015-08-06
The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).
Intra-Cellular Therapies, Inc. | Date: 2015-08-06
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
Intra-Cellular Therapies, Inc. | Date: 2015-06-04
Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Intra-Cellular Therapies, Inc. | Date: 2016-10-26
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT_(2A), SERT and/or dopamine D_(2) pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinsons disease or any combinations.
Intra-Cellular Therapies, Inc. | Date: 2016-03-10
The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycl fused gamma-carbolines.
Intra-Cellular Therapies, Inc. | Date: 2016-01-11
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.
Intra-Cellular Therapies, Inc. | Date: 2015-03-27
The invention provides novel 7,8-dihydro-imidazo[1,2-]pyrazolo[4,3-e]pyrimidin-4-one compounds and 7,8,9-trihydro-[1H or 2/f]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one compounds, substituted at the 1 or 2 position with C2-g allcyl, C3-9 cycloalkyl, heteroarylalkyl, or substituted arylalkyl, in free, salt or prodrug form, processes for their production, their use as pharmaceuticals, particularly as PDE1 inhibitors, and pharmaceutical compositions comprising them.
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 348.09K | Year: 2016
DESCRIPTION provided by applicant Anxiety and depression are prevalent in patients affected by neurodevelopmental disorders including autism spectrum disorders ASD and schizophrenia These co morbid disorders contribute to abnormal social interaction and deficits in interpersonal communication that intensify the social isolation in patients It is noteworthy tht over of ASD patients experience at least one anxiety disorder while co morbid depression is present in the majority of schizophrenia patients Significantly current anti depressant medications are reported to be minimally effective in these patients and often seriously exacerbate hyperactivity aggression and irritability New therapeutic agents that effectively improve mood in patients with these neurodevelopmental disorders without promoting hyperactivity or aggression would be highly significant and are urgently needed Here we propose a one year Phase I SBIR project to advance inhibitors of phosphodiesterase PDE a novel preclinical target for treatment of anxiety and depression into preclinical animal testing as first in class treatments for mood disorders in neurodevelopmental disease The PDE enzyme controls levels of cyclic nucleotides cAMP and cGMP in brain regions involved in cognition and mood including cortex hippocampus and striatum Published tool compounds inhibiting PDE activity display antianxiety like and antidepressant like efficacy in animal behavioral paradigms though these compounds have generally poor bioavailability and exhibit limited brain permeability hindering their clinical development to date Intra Cellular Therapies Inc ITI a clinical stage pharmaceutical company with an established drug discovery platform and expertise in discovering small molecule inhibitors for protein phosphodiesterases PDE has discovered small molecule inhibitors of the enzyme with nM potency good selectivity versus other PDE families and superior bioavailability and brain penetrance versus published compounds ITI proposes to collaborate with Drs James M Oandapos Donnell and Ying Xu at the SUNY at Buffalo experts in the characterization of antianxiety and antidepressant effects of PDE inhibition to test the behavioral efficacy of these molecules We plan to optimize lead PDE inhibitors with comparable or better potency low nM and selectivity versus other PDE family enzymes and improved oral bioavailability and metabolic stability compared with to published compounds e g BAY Up to five compounds will be tested in a panel of antianxiety and antidepressant paradigms in the Ying Oandapos Donnell lab to select molecules with superior efficacy for advancement into a preclinical development program in a future Phase II SBIR application We propose to extend these studies if successful during a Phase II project to investigate the utility and potential side effects of PDE inhibitors in animal models relevant t other features of neurodevelopmental diseases such as ASD including social behavior and hyperactivity PUBLIC HEALTH RELEVANCE Intra Cellular Therapies Inc andquot ITIandquot has a biotechnology platform that has enabled discovery of innovative pharmaceutical therapies for CNS disorders based on intracellular signaling In this project we propose to develop safe brain penetrant drugs targeting a molecular target in the brain that affects intracellular signaling and advance these drugs as treatment for symptoms of depression and anxiety in schizophrenia By screening of the ITIandapos s proprietary compound library we will identify and develop promising drug leads as CNS drug candidates